经动脉化疗栓塞术 (TACE) 市场规模、份额和成长分析（按手术类型、产品类型、适应症、最终用户和地区划分）—2026-2033 年产业预测

预计到 2024 年，经动脉化疗栓塞术 (TACE) 市场规模将达到 106.6 亿美元，到 2025 年将达到 111.4 亿美元，到 2033 年将达到 158.4 亿美元，在预测期（2026-2033 年）内复合年增长率为 4.5%。

全球经动脉化疗栓塞术（TACE）市场正经历显着的变革时期，其主要驱动力是消费者对肝细胞癌（HCC）微创治疗需求的不断增长。随着肝炎感染、饮酒和非酒精性脂肪肝（NFLD）等因素导致全球肝癌发生率上升，TACE市场预计将持续成长。医疗技术的进步，包括影像学、栓塞剂和药物传输系统的创新，提高了TACE手术的精准度和效率，增强了其吸引力。人们对肝癌症状的认识不断提高，促使更多患者寻求早期诊断和治疗方案，从而推动了TACE在中度肝癌治疗中的应用。医疗基础设施和法规结构的区域差异，尤其是在亚太等高发病率地区，持续影响市场动态。

经动脉化疗栓塞术市场驱动因素

全球肝癌发生率的不断上升是经动脉化疗栓塞术（TACE）市场发展的主要驱动因素，因为它推动了对有效治疗方法的需求。医疗技术的进步不断提高这些手术的精准性和有效性，使其对医护人员和患者都更具吸引力。此外，微创治疗的趋势也是推动TACE发展的关键因素，因为与传统治疗方法相比，这些方法通常能减轻患者的不适感。因此，由于疼痛减轻和恢復时间缩短，患者更倾向于选择TACE。

限制经动脉化疗栓塞市场发展的因素

经动脉化疗栓塞术（TACE）市场面临许多挑战，主要原因在于肝癌患者的异质性及其复杂的治疗反应，导致标准化治疗难以实现。这种固有的复杂性要求个别化的治疗方案，从而限制了TACE的广泛应用。此外，严格的核准和报销监管要求也构成了额外的障碍。报销政策的差异和冗长的监管流程可能会阻碍TACE成为主流治疗手段并融入标准医疗实践。因此，这些因素不仅限制了TACE的普及，也限制了其在肝癌治疗领域广泛应用的潜力。

经动脉化疗栓塞术（TACE）市场趋势

经动脉化疗栓塞术（TACE）市场正经历着向个人化医疗的重大转变，强调根据患者个别特征和肿瘤情况制定针对肝癌的客製化治疗方案。这种个人化治疗不仅改善了治疗效果，也契合了肿瘤学领域精准医疗的整体趋势。同时，随着研究不断提高TACE手术的准确性和有效性，市场正经历技术创新的蓬勃发展。栓塞剂、药物释放型微球技术和诊断影像技术的进步，使得更精准的治疗性介入成为可能，从而减少对健康组织的损伤，并改善患者的整体预后。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究
• 技术进步

全球经动脉化疗栓塞术 (TACE) 市场规模（按手术类型和复合年增长率划分）（2026-2033 年）

• 传统TACE
• DEB-TACE

全球经动脉化疗栓塞术（TACE）市场规模（按产品类型和复合年增长率划分）（2026-2033 年）

• 化疗药物
• 放射治疗药物
• 药物释放型颗粒

全球经动脉化疗栓塞术 (TACE) 市场规模（按适应症和复合年增长率划分）（2026-2033 年）

• 无法切除的肝细胞癌
• 早期肝细胞癌（HCC）

全球经动脉化疗栓塞术 (TACE) 市场规模（按最终用户划分）及复合年增长率 (2026-2033)

• 医院和诊所
• 癌症研究中心

全球经动脉化疗栓塞术（TACE）市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Meril Life Sciences（India）
• MicroPort（China）
• Terumo Corporation（Japan）
• Ethicon（Johnson & Johnson）（United States）
• Neusoft Medical Systems Co., Ltd.（China）
• Merit Medical Systems, Inc.（United States）
• Guerbet Group（France）
• AngioDynamics, Inc.（United States）
• Boston Scientific（United States）
• Medtronic（Ireland）
• Beckton Dickinson（United States）
• Cook Group（United States）
• HealthTronics（United States）
• IceCure Medical（Israel）
• Profound Medical（Canada）
• Siemens Healthineers（Germany）
• GE Healthcare（United States）
• Philips Healthcare（Netherlands）
• Sirtex Medical（Australia）
• BTG plc（United Kingdom）

结论与建议

Transarterial Chemoembolization Market size was valued at USD 10.66 Billion in 2024 and is poised to grow from USD 11.14 Billion in 2025 to USD 15.84 Billion by 2033, growing at a CAGR of 4.5% during the forecast period (2026-2033).

The global transarterial chemoembolization (TACE) market is experiencing a significant shift driven by rising consumer demand for minimally invasive treatments for hepatoma. As the global prevalence of liver cancer rises due to factors such as hepatitis infections, alcohol use, and non-alcoholic fatty liver disease, the market for TACE is poised for growth. Advancements in medical technology have enhanced the precision and efficiency of TACE procedures, with innovations in imaging, embolic agents, and drug delivery systems contributing to its attractiveness. Increased awareness of liver cancer symptoms has led more patients to pursue early diagnosis and treatment options, propelling the utilization of TACE for intermediate-grade liver cancer. Regional disparities in healthcare infrastructure and regulatory frameworks continue to shape market dynamics, particularly in high-incidence areas like Asia-Pacific.

Top-down and bottom-up approaches were used to estimate and validate the size of the Transarterial Chemoembolization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Transarterial Chemoembolization Market Segments Analysis

Global Transarterial Chemoembolization Market is segmented by Procedure Type, Product Type, Indication, End-User and region. Based on Procedure Type, the market is segmented into Conventional TACE and DEB-TACE. Based on Product Type, the market is segmented into Chemotherapeutic Agents, Radiotherapeutic Agents and Drug-eluting Particles. Based on Indication, the market is segmented into Unresectable HCC and Early-Stage HCC. Based on End-User, the market is segmented into Hospitals and Clinics and Cancer Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Transarterial Chemoembolization Market

The growing global prevalence of liver cancer is a significant driver for the Transarterial Chemoembolization (TACE) market, as there is an increasing demand for effective treatment options. Advancements in medical techniques are continually enhancing the precision and effectiveness of these procedures, making them more appealing to both healthcare professionals and patients. Additionally, the trend towards minimally invasive treatments serves as a crucial factor in promoting TACE, as these methods typically result in less discomfort compared to conventional treatment approaches. Consequently, patients are more likely to favor TACE due to its reduced pain and recovery times.

Restraints in the Transarterial Chemoembolization Market

The Transarterial Chemoembolization market faces significant challenges primarily due to the varied nature of liver cancer patients and their complex treatment responses, which complicate standardization. This inherent complexity necessitates personalized treatment approaches, limiting TACE's broad application. Additionally, stringent regulatory requirements for approving and reimbursing medical procedures present further obstacles. Variations in reimbursement practices and lengthy regulatory processes can hinder the mainstream integration of TACE into standard healthcare practices. Consequently, these factors collectively restrict not only the adoption of TACE but also its potential to be widely utilized in the treatment landscape for liver cancer.

Market Trends of the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market is witnessing a significant shift towards personalized medicine, emphasizing tailored treatment approaches for liver cancer based on individual patient characteristics and tumor profiles. This customization enhances therapeutic outcomes and aligns with the broader movement towards precision medicine in oncology. Concurrently, the market is experiencing a surge in technological innovations, with ongoing research focused on enhancing the precision and efficacy of TACE procedures. Advances in embolic agents, drug-eluting bead technologies, and imaging capabilities are enabling more targeted therapeutic interventions, reducing collateral damage to healthy tissues and improving overall treatment effectiveness for patients.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Transarterial Chemoembolization Market Size by Procedure Type & CAGR (2026-2033)

• Market Overview
• Conventional TACE
• DEB-TACE

Global Transarterial Chemoembolization Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Chemotherapeutic Agents
• Radiotherapeutic Agents
• Drug-eluting Particles

Global Transarterial Chemoembolization Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Unresectable HCC
• Early-Stage HCC

Global Transarterial Chemoembolization Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Cancer Research Centers

Global Transarterial Chemoembolization Market Size & CAGR (2026-2033)

• North America (Procedure Type, Product Type, Indication, End-User)
  • US
  • Canada
• Europe (Procedure Type, Product Type, Indication, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Procedure Type, Product Type, Indication, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Procedure Type, Product Type, Indication, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Procedure Type, Product Type, Indication, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Meril Life Sciences (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPort (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon (Johnson & Johnson) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neusoft Medical Systems Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merit Medical Systems, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AngioDynamics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckton Dickinson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Group (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HealthTronics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IceCure Medical (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Profound Medical (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirtex Medical (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BTG plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations